Phosphodiesterases (PDEs) are a family of enzymes which catalyse the metabolism of the
intracellular cyclic nucleotides, c-AMP and c-GMP that are expressed in a variety of cell …

Chronic respiratory diseases affect millions of people every day. According to the World
Health Organization estimates,~ 235 million people suffer from asthma,~ 64 million suffer …

PDE4 inhibitors can suppress a variety of inflammatory cell functions that contribute to their
anti-inflammatory actions in respiratory diseases like chronic obstructive pulmonary disease …

Chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and
asthma, affect millions of people all over the world. Cyclic adenosine monophosphate …

Asthma and chronic obstructive pulmonary disease (COPD) are common chronic respiratory
diseases. Both diseases have incompletely distinct pathophysiology, clinical manifestation …

Xanthines like theophylline have long been recognised as being effective drugs for the
treatment of asthma and chronic obstructive pulmonary disease (COPD). They are of interest …

Phosphodiesterase4 inhibitors are currently under development for the treatment of
respiratory diseases including asthma and chronic obstructive pulmonary disease. The …

Abstract Phosphodiesterase 4 (PDE4) is member of the growing family of proteins that
regulate the intracellular concentrations of cyclic AMP and cyclic GMP. Earliest described …

Introduction: Phosphodiesterase (PDE) inhibitors modulate lung inflammation and cause
bronchodilation by increasing intracellular cyclic adenosine 3', 5'-monophosphate in airway …

Phosphodiesterase 4 (PDE4) is a member of the PDE enzyme superfamily that inactivates
cyclic adenosine monophosphate and cyclic guanosine monophosphate, and is the main …